0001628280-24-000888.txt : 20240109 0001628280-24-000888.hdr.sgml : 20240109 20240109075740 ACCESSION NUMBER: 0001628280-24-000888 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lantheus Holdings, Inc. CENTRAL INDEX KEY: 0001521036 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 352318913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36569 FILM NUMBER: 24521738 BUSINESS ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 BUSINESS PHONE: 978 671-8001 MAIL ADDRESS: STREET 1: 331 TREBLE COVE ROAD CITY: NORTH BILLERICA STATE: MA ZIP: 01862 FORMER COMPANY: FORMER CONFORMED NAME: Lantheus MI Holdings, Inc. DATE OF NAME CHANGE: 20110517 8-K 1 lnth-20240109.htm 8-K lnth-20240109
FALSE000152103600015210362023-02-232023-02-23

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2024
LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3656935-2318913
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
201 Burlington Road, South Building, Bedford, MA
01730
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (978) 671-8001
Not Applicable
(Former name or former address, if changed since last report.)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareLNTHThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02.     Results of Operations and Financial Condition.
On January 9, 2024, Lantheus Holdings, Inc. (the “Company”) announced via press release certain unaudited financial results for the twelve months ended December 31, 2023. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1*
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
*    Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
LANTHEUS HOLDINGS, INC.
By:
/s/ Daniel M. Niedzwiecki
Name:
Daniel M. Niedzwiecki
Title:
Chief Administrative Officer and General Counsel
Date: January 9, 2024
 


 EX-99.1 2 exhibit9912023preliminaryr.htm EX-99.1 Document

Exhibit 99.1
newlantheuslogo.jpg
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement
Full year 2023 PYLARIFY revenue expected to be in the range of $851 - 853 million, pending final partner reconciliation, an increase of 61 - 62% over the prior year
Full year 2023 DEFINITY revenue expected to be approximately $279 million, a 14% increase over the prior year
BEDFORD, Mass., January 09, 2024 (GLOBE NEWSWIRE) – Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported certain preliminary unaudited financial results for its fiscal year ended December 31, 2023.
Full Year 2023 Revenue Highlights
Year Ended December 31, 2023
Year Ended December 31, 2022
YoY Change
Worldwide Revenue
$1.295 - 1.297 billion
$935.1 million
+38 - 39%
PYLARIFY Revenue$851 - 853 million$527.4 million+61 - 62%
“Lantheus has consistently exemplified our strong commitment to excellence and has been at the forefront in the ongoing renaissance in the radiopharmaceutical industry,” stated Mary Anne Heino, Chief Executive Officer of Lantheus. “Over the course of the past year, Lantheus has impacted the lives of more than six million patients and their families. Our efforts have resulted in record revenues and a period of exceptional achievement. As we head into 2024, Lantheus is well positioned for growth and to deliver sustained shareholder value, driven by our radiopharmaceutical platform and supported by the dedicated efforts of the Lantheus team to Find, Fight and Follow disease to deliver better patient outcomes.”
Fiscal Year 2023 Revenue
•Worldwide revenue for the full year 2023 is expected to be in the range of $1.295 - 1.297 billion, compared with $0.935 billion for the full year 2022, which would represent an increase of approximately 38 - 39% over the prior year period, exceeding the Company’s previously issued guidance range of $1.255 - 1.270 billion;
•Expected worldwide revenue for the full year 2023, excluding the RELISTOR sales milestone of $15 million, represents an increase of approximately 37% over the prior year period;
•PYLARIFY revenue for the full year 2023 is expected to be in the range of $851 - 853 million, pending final partner reconciliation, compared with $527.4 million for full year 2022, which represents an increase of approximately 61 - 62%; and
•DEFINITY revenue for the full year 2023 is expected to be approximately $279 million, compared with $245.0 million for full year 2022, which represents an increase of approximately 14%.
These preliminary results are unaudited and remain subject to adjustment. Lantheus will provide its fourth quarter and full year 2023 financial results, and further details related to its 2024 financial expectations, in late February 2024.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of
Page 1 of 3

1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “anticipate,” “believe,” “confident,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intend,” “introduce,” “may,” “momentum,” “plan,” “potential,” “predict,” “progress,” “project,” “promising,” “should,” “target,” “will,” “would” and other similar terms. Such forward-looking statements include our preliminary revenue results for fiscal year 2023 and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment in which other imaging agents have been approved and are being commercialized, and our ability to clinically and commercially differentiate our products from other products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility; (iii) the global availability of Molybdenum-99 (“Mo-99”) and other raw material and key components; (iv) the efforts and timing for clinical development, regulatory approval and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (v) our strategies, future prospects, and our projected growth, including revenue related to our collaboration agreements with POINT Biopharma Global Inc.; (vi) our ability to successfully continue existing clinical development partnerships using MK-6240 as a research tool and to further develop and commercialize such research tool; (vii) our ability to identify and acquire or in-license additional diagnostic and therapeutic product opportunities in oncology and other strategic areas and continue to grow our pipeline of products; and (viii) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
Page 2 of 3

###
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
Page 3 of 3
 EX-101.SCH 3 lnth-20240109.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lnth-20240109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 lnth-20240109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 newlantheuslogo.jpg begin 644 newlantheuslogo.jpg MB5!.1PT*&@H -24A$4@ =D !K" , ,[ CZ !)E!,5$7___\ M+05TW4@%@T@ *@ &P )@ * (P!#7T4 + !PW$*BZ(:@K*$ 'P!ZWT_J M^>0 &@ %0 7>406-A4 =S#9WMK@YN%H?&FYQ;HD0B4 $ "EL:;V^?9*74I< M:ER*DXLV4CAO?W"ZO[KK[^N=I)T !P N3# +-@_"RL( !2:%, ?CX #0". MG8^NNZ\ND5]_CX!>J()OL(Z)F(H;/1WY_O:"X%VT[)_:]L_R_.W&\+BHZ8_8 MY]ZKT;W#W]%%FFU9<5HZ73V/P:< . D2B&K-U%)\Q6)>J48G;T9L2O9T +Y4E$051XG.V=:V/:.!:&32-? M,(,9/)2;<6:@G@"!A-# =F=WFS;3-G6;9K?MM)WI[LQ>_O^?6%NRP;IQ-]B. MWD\!R[*DQSY'YT@FDN3I3]^N*DDH1?KVFR>E5?7G0S=6:'7]]*!0>+"B"B7Q MU*9&?RFMS-63()L>_74=L()LBO0W03:C^D:0S:@$V:Q*D,VJ!-FL2I#-J@39 MK$J0S:H$V:Q*D,VJ!-FL2I#-J@39K$J0S:H$V:Q*D,VJ!-FL2I#-J@39K$J0 MS:H$V:Q*D,VJ!-FL2I#-J@39K"HNLO;3JZ=QMEMHF6(B^^SY<#B\M&-MNM!" MQ4+VZ>.'PZ.CH^%ES(V_Y[+=4:O5&KD.\V@,9-]<'OE$>MV&- W;7)_#@]?S@"-;&47M$GIFOT74Z5%E)G3T<'GIJ*J&XLEJ MK7R"/?#/T"IL,(U_C) MPA'VQGC**Q"0U4V6A4\QV3S=4JW7]X]X9-VVTZGU=DK6?G&$@8V;;+4"4*^L M/J]%B*S'GD$AO63/C; 2H(+P3Q7X)_MDFY+MO-PEV7<7.-?8R4Y"$MIK3HF0 M;$Z[I0_29$^,4%IP1\R^,$ZV):L9N,R-R=;.D(/5+/-5_J5E:?"C>N*WQW8E MQ[O/[?[NR#ZCN,9.MJP'9'69,$ZWZJBT.]84SP20S=D162_282A>LJWRS+(9'7:1.=ENO/4)3OV=5N0%97:6A1K4'6F?K7T,'\(NZMID[)4W=#]NJ(?F#C)FL? M*]!=P0=BRN83(0MTLNN+R-K'.R?+FPL@K4&V"HMJ42-DY\^HQNR"[+L[)M>8 MR?;/H'>IP]F$S(QKHF1SJDZ$O6DEBVR5A5W=IMNR/5DBTMD;V=?^\*JW3M=G M "S3$ 6X=4&>!X[K63'!C3&;"LUU[9D[4NV(8Z=;+4'T+-:A ^M2:7?8.L@ M6="$)CMGX@]V6LFBX,SD3!IGVI(LQ\'N@2R\P(^5G.I'&FK5:E&WFRTTK6:<.^ 'G"70GQM3%9 M^\5P&=@XR<)YD]*%?_,'>D96L- ##*W=XLV1-R/[[/D*7.,D&X0\P?A \P04NEB$K(0"7P!FS\Z69'/Z MM$D+608&6;RT3BX^K;4BT !AF*ZK9K/C,G5*7&,D6X5=*X?/'XH# M&"=&R=JWD =00N^T+5GO+J&5XY'%2U-!VGJK>"-YOCP+-"O/"OG6)[N*@XV; M+'S^P,N0$0*HMJE[-TI6JJ&TA78<%-N:+%?+5_'*VY&5W*8\SZ[E%'-*+T"O M399>J]L_6:9"ESN=>!P"6>T(MG"YR^6FM,30=9%.8<<'6U0 M^U,ILN$N-M]T)8LL-#KT'%"JF4O(2E(_<+=G6%=6(_O^0\7O3#+(+IB_@"D^ M0Z3)2F,XA+HQ2A;9/IP!4!.K<$^UL7!0T 22V!"T"MG2QU<&VK>;!+*U"B"! MSF7A<1V#;+#)!O2<1)%%:4F#WAK2@D9&6_Q*S 3>%_C"W@ID/W?+P5@F@NRY M3)GBN4%6\!<]&&0EQT0)B\% 31#96I,=MP4[*-3%Z^RLY:ZE9'_]8LPR68D@ M"Q&"2I<4VM%G8',0%EFIKP;3K5R"R$KP@H!Z5P@E94"%:!YQ:71?X,U=0K;T MV]>(5TL"6;BC0->*5,"!)E8X12;9^0[T))%%:31JP:H(IP5$#YQKXAVTX(E? M^9DME/[H1E-822!K#Q1X#S.6-V P!/0H*399:6 DCZP+HQM=PXNAW5XY&?NV MVC3D:ZQ87Z-O"S[9PH//[*HDC:P]08@M# MZ[Y$6T&.HS=RRW\E0,9>"H;[$')GV"7X9-]_^%W)X=H+6;EHDX8VTB_^_@E) M0BY)CY3FD/5FHJ$IVAM9T""[19@==&-Z[G\/9*EN&>0^6KL=3%:! M)I=-_V<*T$>MBQ6T!^$$4#7*UID5+OBH.EX?@VRA]/F+ACO8O9*E%-E+K%&K M/%&A^65DNL$G:[>5/9-=T*NP_UU6=DUK$J['N949XP1TPI'39 M/?ON=D[\[ M.%GX2HO.3;558:2JS4,"/MEPAT62R$JU6YFTE+K84SH VJ$JPVV\NDFSA MR1__,GCINT.3M6]A.-_CUO :!3XS8[V K-300-+(2M*YA@T^,&3FJP"MJ:E$ MQDI739H_3K90^N43/7':&UG/N;!DY8,QZ)_Z!4[YOQ+DGOKE3V>C8IG_EGLM[L=% #\)V&I^Q>';.V'%8[S;*APFRI MJI6G8]XKW\6WH*RA6?:Z(+8#*^VI%>$:OUQ^^9KI?*U7>?N M)?:O5&U==[UR-S>#<^:VU)\*$4/L.5BV/=P/6:&YJ'"75XY[I/J^,'.P-UP' MNR'9-7_#36BG^C=$6RC]AQ/I;$/V[M"=N]QF9(>/#]VY>RV[ M7=:^5HS%#G9#LN\.W;G[K;XYVR"V8[(7;P[=MWNN,3N2WIKL\,6A>W;O-3;C M>&:'S\5/DA]-'= MLT/W2"B0?3XUED4^*Y,=/E[XLR="^U6MOBQ;L2+9X84(9!.F?MY::))7(CL4 MT4X2-6I2J_KKD1T>78K\1"+EC'5^!+2<[/"YB'42J^K XKG;962'=\+!)EK] M/" XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Feb. 23, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 09, 2024
Entity Registrant Name LANTHEUS HOLDINGS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36569
Entity Tax Identification Number 35-2318913
Entity Address, Address Line One 201 Burlington Road, South Building
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code 978
Local Phone Number 671-8001
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol LNTH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001521036
XML 8 lnth-20240109_htm.xml IDEA: XBRL DOCUMENT 0001521036 2023-02-23 2023-02-23 false 0001521036 8-K 2024-01-09 LANTHEUS HOLDINGS, INC. DE 001-36569 35-2318913 201 Burlington Road, South Building Bedford MA 01730 978 671-8001 false false false false Common stock, par value $0.01 per share LNTH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #,_*5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " S/RE8";N)<>\ K @ $0 &1O8U!R;W!S+V-O&ULS9++ M3L,P$$5_!7F?3)SPM-)L0*Q 0J(2B)UE3UN+^"%[4-*_)S%M*@0?T*5GKL^< MD:9502@?\27Z@)$,IHO1]BX)%59L1Q0$0%([M#*54\)-S8V/5M+TC%L(4GW* M+4)=5==@D:26)&$&%F$ALJ[52JB(DGP\X+5:\.$K]AFF%6"/%ATEX"4'ULT3 MPW[L6S@!9AAAM.FG@'HAYNJ_V-P!=DB.R2RI81C*H&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" S/RE8-=V>2EP$ "3$ & 'AL+W=O M&6+367/,?HEMV>?ED8[T'BG]O51OR98Q3=ZC4"0#:ZMU?&O;B;]E$4WJ,F8" MWJREBJB&1[6QDU@Q&F1!46A[CM.V(\J%->QG;7,U[,M4AURPN2))&D54'>Y8 M*/<#R[4^&E[Y9JM-@SWLQW3#%DQ_B><*GNQ<)> 1$PF7@BBV'E@C]_;.:YJ M[(N_.-LG9_?$=&4EY9MYF 8#RS%$+&2^-A(4+CLV9F%HE(#CVTG4RG_3!)[? M?Z@_9)V'SJQHPL8R_,H#O1U878L$;$W34+_*_2,[=:AE]'P9)ME?LC]^VVQ: MQ$\3+:-3,!!$7!RO]/TT$.Z+,UZ!F;K*N M9M$ QX7)RD(K>,LA3@_'(T:\1RO\?]P M&PAR#"_'\#*]!H9!_AFM$JT@4?^6$1T5FN4*9O;>)C'UV<""Z9DPM6/6\)>? MW+;S.\+7R/D:F/KP7OHIS$5-EH>8E<'AX=V;SPA$,X=H7@C5B$MA$V%HY6PM5G C-]8&\L@TW*03(&8U*R7"=I]%L^3CY MLB"/+T_WT]FG1>V8P^EL7$HY+[E(%S1L-O7R5-( 9 @5M"\T\#* =X7:=PGB='R(?FR>8@TNY%Z6&C,O= ML0!J=("AG=4$]X?0\O4Q5W+'A5\ZJA6:SR,,K:@3+FKSWZ'-9:)I2/[F\<5% M6Z'HN)V&@[$5-<+%73[+X CV1I=1<(%>IXN!%'7"Q>W]2?HP)O.M%)B'5(BT M.^Y-%YP$(RJJ@XO;^E?%M68"!B:*4G%RD*24"A=:TS!A&%)1"5SQ4"3[!5PD@*O_=P;_X8,#)Y][=4;-C%S5N%T&RTN!_]B3&='0BN,OI)Q-3& MC-(G4( 2# F*J2A-;85@U73S"I_W<)L>P2((LH7P$-)-*0HN4(E2.+V'F_1I ME,8 H\#RI[ @W\EG5CX^N)0#7M_R7*?1+B.SSXZ8YKC^3$U:$A*R-:@Y]0[8 MMCJ>@(\/6L;9J7,E-9QAL]LMH^ 7Y@-XOY92?SR8@VS^?XCA?U!+ P04 M" S/RE8GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK M6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9) ML;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2 MVSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK= M5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>6 M5Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEU MXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z M6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$// M\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?# M$T%^@2O&+(=/EB>N$_N MG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"= MXI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C% M^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[*CG_ M5U/\!%!+ P04 " S/RE8EXJ[', 3 @ "P %]R96QS+RYR96QS MG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2 MW!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N M&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,E MC'%BM/XU@LD/['X 4$L#!!0 ( #,_*5BJQ"(6,P$ "(" / >&PO M=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O' MA8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02=5,3> MBD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0# M.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2' MV#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T M/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+()FKJ MIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ M_)[E#U!+ P04 " S/RE8)!Z;HJT #X 0 &@ 'AL+U]R96QS+W=O M[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E* M%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,) MKM\,<'AT_@%02P,$% @ ,S\I6&60>9(9 0 SP, !, !;0V]N=&5N M=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2 MVS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\ MFK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+,:DH9 MHS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM M0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I- M"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O& M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " S/RE8!T%-8H$ M "Q $ @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 M Q0 ( #,_*5@)NXEQ[P "L" 1 " :\ !D;V-0 M&UL4$L! A0#% @ M,S\I6#7=GDI&UL4$L! A0#% @ ,S\I6)>* MNQS $P( L ( !? \ %]R96QS+RYR96QS4$L! A0# M% @ ,S\I6*K$(A8S 0 (@( \ ( !91 'AL+W=O M7!E&UL4$L%!@ ) D /@( /03 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.lantheus.com/role/Cover Cover Cover 1 false false All Reports Book All Reports lnth-20240109.htm lnth-20240109.xsd lnth-20240109_lab.xml lnth-20240109_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lnth-20240109.htm": { "nsprefix": "lnth", "nsuri": "http://www.lantheus.com/20240109", "dts": { "inline": { "local": [ "lnth-20240109.htm" ] }, "schema": { "local": [ "lnth-20240109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "lnth-20240109_lab.xml" ] }, "presentationLink": { "local": [ "lnth-20240109_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "report": { "R1": { "role": "http://www.lantheus.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20240109.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "lnth-20240109.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.lantheus.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001628280-24-000888-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-000888-xbrl.zip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